Every 10-Q that Arcturus Therapeutics Holdings Inc. (ARCT) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ARCT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ARCT filings page.
Arcturus Therapeutics reported Q1 2026 revenue of $2.1 million, sharply down from $29.4 million a year earlier, mainly due to lower collaboration revenue from CSL Seqirus and reduced BARDA grant revenue. Net loss widened to $27.0 million, or $0.95 per share, from $14.1 million.
Operating expenses fell as research and development dropped to $21.5 million and general and administrative to $9.5 million, reflecting lower LUNAR‑COVID spending, BARDA activity, headcount and stock‑based compensation. Arcturus ended the quarter with $213.4 million in cash, cash equivalents and restricted cash and no debt, and believes this will fund operations for at least the next twelve months.
Clinically, the company advanced its rare‑disease RNA therapeutics: Phase 2 dosing progressed for cystic fibrosis candidate ARCT‑032 and enrollment continued in the Phase 2 OTC‑deficiency study ARCT‑810, with recent FDA feedback outlining steps toward a pivotal pediatric trial. Its partnered sa‑mRNA COVID‑19 vaccine KOSTAIVE gained UK marketing authorization, while collaboration partner CSL Limited recorded an approximately $430 million accounting write‑down related to the relationship, underscoring uncertainty around long‑term COVID‑19 vaccine demand and regulatory pathways.
Arcturus Therapeutics (ARCT) reported Q3 2025 results. Total revenue was $17.2 million, driven by collaboration revenue of $14.2 million (including $13.6 million from CSL Seqirus) and grant revenue of $3.0 million. The company posted a net loss of $13.4 million, or $0.49 per share.
Operating expenses declined as programs matured: research and development fell to $23.3 million and general and administrative to $10.4 million. Cash and cash equivalents were $180.4 million; total cash, cash equivalents and restricted cash were $237.2 million at quarter end. Deferred revenue decreased as COVID-19 vaccine activities transitioned from development to commercial phases under the CSL collaboration.
Regulatory updates were mixed. The European Commission approved KOSTAIVE (ARCT-154) for adults earlier in 2025, while in October the FDA indicated a Biologics License Application for KOSTAIVE would require additional data from a clinical endpoint efficacy study. As of November 5, 2025, 28,412,537 shares of common stock were outstanding.
Arcturus reported lower collaboration-driven revenue as its COVID-19 vaccine transitioned to commercialization, while advancing clinical programs and recognizing milestone payments.
Total revenue for the quarter was $28.3 million versus $49.9 million a year earlier, driven by $24.4 million of collaboration revenue from CSL Seqirus and $3.8 million of grant revenue from BARDA. Net loss was $9.18 million for the quarter and $23.26 million for the six months. Cash and restricted cash totaled $253.4 million, and the accumulated deficit was $472.1 million.
The company highlighted regulatory and commercial progress for KOSTAIVE (ARCT-154) with approvals in Japan and the EU, receipt of a $200.0 million upfront payment from CSL and approximately $509.7 million of total upfronts and milestones to date, including a $20.0 million development milestone recognized this quarter. Research and development and general and administrative expenses declined year-over-year as programs shifted toward commercialization.